Behavior and Genetic Risk | GenomeWeb

Behavior and Genetic Risk

Premium

As a health psychologist at King's College, London, who studies people's responses to genetic test results, Theresa Marteau says that just informing people about their genetic risk often won't motivate them to change their lifestyle. Genome Technology's Ciara Curtin recently spoke with Marteau about her work. What follows is an excerpt of their conversation, edited for space.

Genome Technology: One of the tenets of personalized medicine is that knowing a person's genetic predispositions will lead to earlier interventions. Do you think that will be the case?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.